Acorda Therapeutics, Inc. announced that data showing treatment with dalfampridine improved motor function in a preclinical model of post-stroke deficits have been published online ahead of print on May 7th in Stroke, a peer-reviewed journal of the American Heart Association. The data will be included in the July 2013 print edition of Stroke. Dalfampridine is the active ingredient in AMPYRA(R) (dalfampridine) Extended Release Tablets, 10 mg. These preclinical data showed that dalfampridine can improve motor function long after a stroke, when the natural recovery process has ended and stable deficits are likely to persist over time. The results informed decision to conduct a recently completed proof-of-concept study in humans, which indicated that dalfampridine improved walking in people with post-stroke deficits.

Acorda Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported total revenues of $71.865 million compared to $71.248 million a year ago. Operating loss was $2.496 million compared to operating income of $8.855 million a year ago. Loss before income taxes was $2.914 million compared to income before income taxes of $8.218 million a year ago. Net loss was $1.139 million or $0.03 per diluted share compared to net income of $7.846 million or $0.19 per diluted share a year ago. Non-GAAP net income was $3.794 million or $0.09 per diluted share compared to $14.537 million or $0.36 per diluted share a year ago. Cash equivalents and investments totaling $324.9 million. The company confirmed its 2013 net sales guidance of $285 million to $315 million.

Acorda Therapeutics, Inc., Q1 2013 Earnings Call, May 02, 2013